Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0AUCH)

Drug Name
Reslizumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Severe asthma CA23 Approved [1]
Eosinophilic asthma CB02.0 Phase 3 [2]
Asthma CA23 Phase 2 [3]
Cross-matching ID
TTD Drug ID
DM0AUCH

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-5 (IL5) TTPREZD IL5_HUMAN Modulator [4]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Nasal and bronchial airway
The Studied Disease Asthma [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-5 (IL5) DTT IL5 4.22E-01 -0.01 -0.04
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8091).
3 ClinicalTrials.gov (NCT00587288) Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
4 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.